mRTVP-1, a novel p53 target gene with proapoptotic activities

被引:59
作者
Ren, CH
Li, LK
Goltsov, AA
Timme, TL
Tahir, SA
Wang, JX
Garza, L
Chinault, AC
Thompson, TC
机构
[1] Baylor Coll Med, Scott Dept Urol, Houston, TX 77030 USA
[2] Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA
[3] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA
[4] Baylor Coll Med, Dept Radiol, Houston, TX 77030 USA
关键词
D O I
10.1128/MCB.22.10.3345-3357.2002
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
We identified a novel mouse gene, mRTVP-1, as a p53 target gene using differential display PCR and extensive promoter analysis. The mRTVP-1 protein has 255 amino acids and differs from the human RTVP-1 (hRTVP-1) protein by two short in-frame deletions of two and nine amino acids. RTVP-1 mRNA was induced in multiple cancer cell lines by adenovirus-mediated delivery of p53 and by gamma irradiation or doxorubicin both in the presence and in the absence of endogenous p53. Analysis of RTVP-1 expression in nontransformed and transformed cells further supported p53-independent gene regulation. Using luciferase reporter and electrophoretic mobility shift assays we identified a p53 binding site within intron 1 of the mRTVP-1 gene. Overexpression of mRTVP-1 or hRTVP-1 induced apoptosis in multiple cancer cell lines including prostate cancer cell lines 148-1PA, 178-2BMA, PC-3, TSU-Pr1, and LNCaP, a human lung cancer cell line, H1299, and two isogenic human colon cancer cell lines, HCT116 p53(+/+) and HCT116 p53(-/-), as demonstrated by annexin V positivity, phase-contrast microscopy, and in selected cases 4',6'-diamidino-2-phenylindole staining and DNA fragmentation. Deletion of the signal peptide from the N terminus of RTVP-1 reduced its apoptotic activities, suggesting that a secreted and soluble form of RTVP-1 may mediate, in part, its proapoptotic activities.
引用
收藏
页码:3345 / 3357
页数:13
相关论文
共 48 条
[1]   Death receptors: Signaling and modulation [J].
Ashkenazi, A ;
Dixit, VM .
SCIENCE, 1998, 281 (5381) :1305-1308
[2]   SUPPRESSION OF HUMAN COLORECTAL-CARCINOMA CELL-GROWTH BY WILD-TYPE-P53 [J].
BAKER, SJ ;
MARKOWITZ, S ;
FEARON, ER ;
WILLSON, JKV ;
VOGELSTEIN, B .
SCIENCE, 1990, 249 (4971) :912-915
[3]   PROGRESSION TO ANDROGEN INSENSITIVITY IN A NOVEL IN-VITRO MOUSE MODEL FOR PROSTATE-CANCER [J].
BALEY, PA ;
YOSHIDA, K ;
QIAN, W ;
SEHGAL, I ;
THOMPSON, TC .
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 1995, 52 (05) :403-413
[4]   Disruption of p53 in human cancer cells alters the responses to therapeutic agents [J].
Bunz, F ;
Hwang, PM ;
Torrance, C ;
Waldman, T ;
Zhang, YG ;
Dillehay, L ;
Williams, J ;
Lengauer, C ;
Kinzler, KW ;
Vogelstein, B .
JOURNAL OF CLINICAL INVESTIGATION, 1999, 104 (03) :263-269
[5]  
Burns TF, 1999, J CELL PHYSIOL, V181, P231, DOI 10.1002/(SICI)1097-4652(199911)181:2<231::AID-JCP5>3.0.CO
[6]  
2-L
[7]   CRYSTAL-STRUCTURE OF A P53 TUMOR-SUPPRESSOR DNA COMPLEX - UNDERSTANDING TUMORIGENIC MUTATIONS [J].
CHO, YJ ;
GORINA, S ;
JEFFREY, PD ;
PAVLETICH, NP .
SCIENCE, 1994, 265 (5170) :346-355
[8]  
Eastham JA, 1995, CLIN CANCER RES, V1, P1111
[9]   Regulation of p53 downstream genes [J].
El-Deiry, WS .
SEMINARS IN CANCER BIOLOGY, 1998, 8 (05) :345-357
[10]   DEFINITION OF A CONSENSUS BINDING-SITE FOR P53 [J].
ELDEIRY, WS ;
KERN, SE ;
PIETENPOL, JA ;
KINZLER, KW ;
VOGELSTEIN, B .
NATURE GENETICS, 1992, 1 (01) :45-49